(Q37955050)

25 August 2017

title

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial (English)

1 reference

25 August 2017

0 references

Nathalie Chabbert-Buffet

8

object named as

Nathalie Chabbert-Buffet

0 references

Suzette Delaloge

5

object named as

Suzette Delaloge

1 reference

25 August 2017

Laurence Gladieff

22

0 references

Christine Lasset

2

object named as

Christine Lasset

1 reference

25 August 2017

14

Paul Gesta

1 reference

25 August 2017

3

Pascaline Berthet

1 reference

25 August 2017

6

Jean-Pierre Fricker

1 reference

25 August 2017

18

Capucine Delnatte

1 reference

25 August 2017

20

Alain Lortholary

1 reference

25 August 2017

1

Pascal Pujol

1 reference

25 August 2017

Catherine Dugast

4

1 reference

25 August 2017

Isabelle Tennevet

7

1 reference

25 August 2017

Pascale This

9

1 reference

25 August 2017

Karen Baudry

10

1 reference

25 August 2017

Jerome Lemonnier

11

1 reference

25 August 2017

Lise Roca

12

1 reference

25 August 2017

Sylvie Mijonnet

13

1 reference

25 August 2017

Jean Chiesa

15

1 reference

25 August 2017

Helene Dreyfus

16

1 reference

25 August 2017

Philippe Vennin

17

1 reference

25 August 2017

Yves Jean Bignon

19

1 reference

25 August 2017

Fabienne Prieur

21

1 reference

25 August 2017

Anne Lesur

23

1 reference

25 August 2017

Krishna B Clough

24

1 reference

25 August 2017

Catherine Nogues

25

1 reference

25 August 2017

Anne-Laure Martin

26

1 reference

25 August 2017

French Federation of Cancer Centres (FNCLCC)

27

1 reference

25 August 2017

language of work or name

1 reference

1 March 2012

1 reference

25 August 2017

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

77-84

1 reference

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Clinical practice. Management of an inherited predisposition to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Time to reconsider subcutaneous mastectomy for breast-cancer prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Are mastectomy rates really increasing in the United States?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

The increasing use of prophylactic mastectomy in the prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Should the use of contralateral prophylactic mastectomy be increasing as it is?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Prophylactic oophorectomy in women at increased cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Is BRCA1/BRCA2-related breast carcinogenesis estrogen dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Exemestane for breast-cancer prevention in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Impact of aromatase inhibitors on bone health in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Managing the toxicities of the aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Uptake of breast cancer prevention and screening trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10689-011-9484-4

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

21 January 2018

1 reference

12 December 2020

Chemoprevention of breast cancer with selective oestrogen-receptor modulators

1 reference

12 December 2020

Uptake of screening and prevention in women at very high risk of breast cancer

1 reference

12 December 2020

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers

1 reference

12 December 2020

Variation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO)

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1007/S10689-011-9484-4

Identifiers

DOI

1 reference

release_iu7kz6rxojgj5exdrn6dlcuery

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iu7kz6rxojgj5exdrn6dlcuery

24 November 2022

mapped directly with Wikidata item

1 reference